I recall we covered this topic before in relation to the R&D claim, they ceased when annual turnover exceeded $20M, that's where Evolis is heading so they would lose that combined. There have been some changes to the rules since which I'm not up to date with but I think its still a valid reason.
CDY Price at posting:
27.0¢ Sentiment: Buy Disclosure: Held
